Journal
VACCINES
Volume 9, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9050532
Keywords
hepatocellular carcinoma; immune checkpoint molecules; immune checkpoint inhibitors; immune microenvironment
Categories
Funding
- Ministry of Health, Italian Government
Ask authors/readers for more resources
Hepatocellular carcinoma is a common and deadly cancer around the world. Traditional treatments like surgery, radiotherapy, and targeted therapies have been used, but due to the immune suppressive nature of HCC, immunotherapy with immune checkpoint inhibitors has shown great promise in recent clinical studies.
Hepatocellular carcinoma (HCC) is one of most common cancers and the fourth leading cause of death worldwide. Commonly, HCC development occurs in a liver that is severely compromised by chronic injury or inflammation. Liver transplantation, hepatic resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), and targeted therapies based on tyrosine protein kinase inhibitors are the most common treatments. The latter group have been used as the primary choice for a decade. However, tumor microenvironment in HCC is strongly immunosuppressive; thus, new treatment approaches for HCC remain necessary. The great expression of immune checkpoint molecules, such as programmed death-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), lymphocyte activating gene 3 protein (LAG-3), and mucin domain molecule 3 (TIM-3), on tumor and immune cells and the high levels of immunosuppressive cytokines induce T cell inhibition and represent one of the major mechanisms of HCC immune escape. Recently, immunotherapy based on the use of immune checkpoint inhibitors (ICIs), as single agents or in combination with kinase inhibitors, anti-angiogenic drugs, chemotherapeutic agents, and locoregional therapies, offers great promise in the treatment of HCC. This review summarizes the recent clinical studies, as well as ongoing and upcoming trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available